Replay, a genome writing company, announced that it has entered into separate agreements with the National Institutes of Health (NIH) and Miltenyi Biotec, a provider of products and services for biomedical research and cellular therapy, that will lead to the development and manufacture of T-cell receptor (TCR) and natural killer (NK) cell-based cell therapies.
Under an exclusive, worldwide license agreement with NIH, Replay will have access to intellectual property (IP) related to a library of TCRs directed against multiple cancer neoantigens. Replay’s oncology-focused product company, Syena, will develop and thus expand its pipeline of engineered TCR–NK cell therapies based on this IP.
